FN1 and neoplasm: Treatment with anti-uPAR antibody (R2) disrupted the uPAR/α5β1 integrin complex, assessed using fibronectin fibril formation assay, immunofluorescence microscopy, Western blot for phospho-ERK inhibition, and co-immunoprecipitation of surface-biotinylated proteins. In vivo confirmation by CAM tumor growth assay.